Bioton takes on insulin giants


Polish company Bioton S.A (Warsaw) and Swiss-headquartered generics giant Actavis (Zug) have joined forces to shake up the €12bn world market for recombinant insulins and insulin analogues. At the end of January, Bioton Chairman Ryszard Krauze and Actavis CEO Claudio Albrecht announced that their companies have formed a joint venture for the development and registration of recombinantly produced insulins. While Bioton will develop and produce the insulins, the fourth largest generics producer will sell them in all EU countries, the US, Japan, Switzerland, Norway, Albania, Bosnia & Herzegovina, Croatia, Iceland, Kosovo, Liechtenstein, Montenegro and Macedonia. In Poland, both companies will market the products under their repective brands.

Facing off with the big boys

Under the terms of the agreement, Bioton will receive €22.25m upfront and a further €33.25m in milestones. Both companies expect revenues to reach €1.5bn in the seven years following the market launches of Bioton’s human recombinant insulin, short-acting insulins and long-acting insulins, the first step of which will commence at the end of 2012. The companies will share profits on a 50/50 basis. Actavis also secured an option to market Bioton’s insulins in 24 further markets, paying the Polish bioech firm €1m up front and €0.9m in milestone payments for the privilege.
For Bioton, which is the fourth firm globally to manufacture a human recombinant insulin (“gensulin”), the deal is a unique opportunity for expansion into the global market, which is currently dominated by three big players: Danish Novo Nordisk, French Sanofi and US pharma giant Eli Lilly. “For Bioton, the collaboration with Actavis will fuel faster expansion into high-margin markets,” commented the firm’s CEO Slawomir Ziegert. Albrecht said the deal involved more than just the sale of insulins and insulin analogues. “We are encountering competitor giants when it comes to insulin, and we have to maximise the competitive advantage that we clearly have.”
Bioton wants to be the first company on the market to offer biosimilar versions of recombinantly-produced human insulins, which will be much cheaper than IP-protected originator products. But Pfizer and its Indian manufacturing partner Biocon are hard on the heels of the Polish. Some insulins – such as Lilly’s Humulin, Novo Nordisk’s Novalin or Sanofi’s Lantus – have already lost patent protection. Others, like Levemir (Novo Nordisk) or the fast-acting insulins Humalog (Eli Lilly) and Novalog (Novo Nordisk) will follow in the next two years.
But Actavis also has plans beyond insulin. Albrecht announced the firm intends to launch a biosimilar for bestselling drugs every month during the first eight months of 2012. Bioton can benefit from the generics expert’s plans. Together with the initial announcement of the diabetes pact, which dates back to November 2010, Actavis said it will carry out a due diligence to acquire a 51% stake in Bioton’s Swiss subsidiary Biopartners – a biosimilar specialist.



Polish antibody development and manufacturing specialist Mabion S.A. more than tripled its revenues in 2011 (€2.5m) compared to 2010 (€0.74m). The increase in turnover mainly resulted from stronger client demand for R&D services...



Zug/Warsaw - The fourth largest generics producer and a polish biotech want to create a stir in the market for diabetes drugs. Swiss Actavis and Bioton from Warsaw announced that they have formed a joint venture company for the...



Krakow – Polish Selvita S.A., which offers preclinical drug development services to pharma companies, has been ranked as the No. 1 “Rising Star” of this year’s Fast50 contest. In the programme, analysts from Deloitte Technology...



Warsaw – Poland’s Bioton S.A. has announced it is investing €20m in a new production plant in Szczecin. The biotechnology company is planning to manufacture insulin injection devices in the facility. The project involves the...



Warsaw – Biotech experts want to make the development of pharmaceutical and medical innovations a priority in Poland. At the start of September, members of the Polish Technology Platform for Innovative Medicine recommended that...



Kraków – Selvita SA CEO Pawel Przewiezlikowski announced at the end of July that the Polish drug development and drug discovery service firm is close to achieving profitability. After bagging EUR3.7m through an IPO on Warsaw’s...



Warsaw – Researchers from Lodz and Poznan Universities say Poland needs to update its draft GMO law. “The national current legal situation is complicated,” Prof. Tomas Twardowski told EuroBiotechNews, stressing that while trade...



Krakow – Polish Selvita S.A. is going public. By May, the drug discovery specialist announced it had entered into definite agreements with investors to sell 2.7 million shares for a total of EUR3.75m, resulting in a market...



Szczecin/Greifswald – A team of physical chemists headed by Robert Hoylst from the Polish Academy of Science have improved a method for calculating the migration time of drugs or drug delivery devices introduced into the sol/gel...



Krakow –Polish drug discovery company Selvita has entered into definitive agreements with investors in Poland to sell, in a private placement, 2.7 million shares of its stock at a price of PLN 5.5 per share, resulting in gross...

Displaying results 1 to 10 out of 108

1-10 Next >

© 2007-2016 BIOCOM



Current issue

All issues

Product of the week


Stock list

All quotes


  • PLETHORA (UK)3.38 GBP12.67%
  • ALMIRALL (E)14.43 EUR7.93%


  • 4SC (D)2.59 EUR-20.31%
  • FORMYCON (D)20.15 EUR-4.37%


  • GALAPAGOS (B)51.86 EUR30.7%
  • NICOX (F)11.00 EUR28.7%
  • GENMAB (DK)1177.00 DKK22.2%


  • MOBERG PHARMA (S)38.00 SEK-21.8%
  • 4SC (D)2.59 EUR-21.5%
  • FORMYCON (D)20.15 EUR-18.0%


  • KARO BIO (S)30.60 SEK1981.6%
  • CHRONTECH PHARMA (S)0.34 SEK1600.0%
  • NICOX (F)11.00 EUR491.4%


  • BB BIOTECH (D)44.03 EUR-84.5%
  • BIOTEST (D)17.15 EUR-78.1%

No liability assumed, Date: 28.05.2016


All Events



Biomedica 2016

Basel (CH)

Chemspec Europe 2016